Original Research
Editorial Comment
One Step Forward and Two Steps Back With Drug-Eluting-Stents: From Preventing Restenosis to Causing Late Thrombosis and Nouveau Atherosclerosis

https://doi.org/10.1016/j.jcmg.2009.01.011Get rights and content
Under an Elsevier user license
open archive

Key Words

drug-eluting stent
atherosclerosis
pathology

Cited by (0)

Dr. Virmani has received research support from 3F Therapeutics, Abbott Vascular, Amaranth Medical, Inc., Apnex Medical, Ardian, Inc., Atrium Medical Corporation, CardioDex Ltd, CardioKinetix, Inc., CorAssist Cardiovascular Ltd, Cordis Corporation, Devax, Inc., ev3, Gardia Medical Ltd, GlaxoSmithKline, HemCon, Lutonix, Inc., Medtronic Vascular, Meril Life Sciences Pvt Ltd, Microvention, Inc., Novartis Pharmaceuticals Corporation, NovoStent Corporation, Oregon Medical Laser Center, Prescient Medical, Inc., Relisys Medical Devices Limited, Vascular Therapies LLC, and Xtent, Inc.; and he is a consultant for Medtronic AVE, Abbott Vascular, W.L. Gore, Volcano Therapeutics, Inc., Prescient Medical, CardioMind, Inc., Direct Flow, and Atrium Medical Corporation.

Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.